{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:03:01Z","timestamp":1793134981033,"version":"4.5.0"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ejphar.2025.177458","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T12:31:22Z","timestamp":1741955482000},"page":"177458","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Tedizolid for osteoarticular infections: Evaluation of the published evidence"],"prefix":"10.1016","volume":"998","author":[{"given":"Veatriki","family":"Athanasiou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Ragias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Tzikopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michalis","family":"Zenios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8068-8575","authenticated-orcid":false,"given":"Matthew E.","family":"Falagas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejphar.2025.177458_bib1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/jac\/dky473","article-title":"Evaluation of the ability of linezolid and tedizolid to eradicate intraosteoblastic and biofilm-embedded Staphylococcus aureus in the bone and joint infection setting","volume":"74","author":"Abad","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"issue":"4","key":"10.1016\/j.ejphar.2025.177458_bib2","article-title":"Antimicrobial resistance in methicillin-resistant staphylococcus aureus","volume":"30","author":"Ali","year":"2023","journal-title":"Saudi J. Biol. Sci."},{"issue":"6","key":"10.1016\/j.ejphar.2025.177458_bib3","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1097\/IPC.0000000000000623","article-title":"Long-term safety of tedizolid in a patient with spondilodiscitis after switch from linezolid due to toxicity","volume":"26","author":"\u00c1lvarez","year":"2018","journal-title":"Infect. Dis. Clin. Pract."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177458_bib4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/antibiotics10010053","article-title":"Long-term use of tedizolid in osteoarticular infections: benefits among oxazolidinone drugs","volume":"10","author":"Benavent","year":"2021","journal-title":"Antibiotics"},{"issue":"12","key":"10.1016\/j.ejphar.2025.177458_bib5","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1097\/INF.0000000000001309","article-title":"Epidemiology and management of acute, uncomplicated septic arthritis and osteomyelitis: Spanish multicenter study","volume":"35","author":"Calvo","year":"2016","journal-title":"Pediatr. Infect. Dis. J."},{"issue":"6","key":"10.1016\/j.ejphar.2025.177458_bib6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.17199","article-title":"Antimicrobial resistance patterns of outpatient Staphylococcus aureus isolates","volume":"7","author":"Carrel","year":"2024","journal-title":"JAMA Netw. Open"},{"issue":"7","key":"10.1016\/j.ejphar.2025.177458_bib7","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/jac\/dkz120","article-title":"Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA and Europe (2014\u201317)","volume":"74","author":"Carvalhaes","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"issue":"2","key":"10.1016\/j.ejphar.2025.177458_bib8","doi-asserted-by":"crossref","first-page":"150","DOI":"10.7861\/clinmedicine.18-2-150","article-title":"Bone and joint infection","volume":"18","author":"Colston","year":"2018","journal-title":"Clin. Med."},{"key":"10.1016\/j.ejphar.2025.177458_bib9","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/jac\/dkh191","article-title":"Antibiotic treatment of gram-positive bone and joint infections","volume":"53","author":"Darley","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"issue":"5","key":"10.1016\/j.ejphar.2025.177458_bib10","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1302\/0301-620X.94B5.28523","article-title":"Haematogenous acute and subacute paediatric osteomyelitis: a systematic review of the literature","volume":"94","author":"Dartnell","year":"2012","journal-title":"J Bone Joint Surg Br"},{"key":"10.1016\/j.ejphar.2025.177458_bib11","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/ejhpharm-2018-001752","article-title":"Hypertensive crisis following the administration of tedizolid: possible serotonin syndrome","volume":"27","author":"De Castro","year":"2020","journal-title":"Eur. J. Hosp. Pharm."},{"key":"10.1016\/j.ejphar.2025.177458_bib12","article-title":"Surgery's role in contemporary osteoarticular infection management","volume":"10","author":"De Marco","year":"2023","journal-title":"Front Pediatr"},{"key":"10.1016\/j.ejphar.2025.177458_bib13","doi-asserted-by":"crossref","first-page":"930","DOI":"10.3390\/antibiotics11070930","article-title":"The association between biofilm formation and antimicrobial resistance with possible ingenious bio-remedial approaches","volume":"11","author":"Dutt","year":"2022","journal-title":"Antibiotics"},{"issue":"7","key":"10.1016\/j.ejphar.2025.177458_bib14","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00228-023-03500-9","article-title":"Linezolid-associated serotonin toxicity: a systematic review","volume":"79","author":"Elbarbry","year":"2023","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177458_bib15","series-title":"Antimicrobial Resistance in the EU\/EEA (EARS-Net) - Annual Epidemiological Report 2023","year":"2024"},{"issue":"9","key":"10.1016\/j.ejphar.2025.177458_bib16","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2165\/00002018-200831090-00004","article-title":"Benefit-risk assessment of linezolid for serious gram-positive bacterial infections","volume":"31","author":"Falagas","year":"2008","journal-title":"Drug Saf."},{"issue":"3","key":"10.1016\/j.ejphar.2025.177458_bib17","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ijantimicag.2006.08.030","article-title":"Linezolid for the treatment of adults with bone and joint infections","volume":"29","author":"Falagas","year":"2007","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"9","key":"10.1016\/j.ejphar.2025.177458_bib18","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/clm.12031","article-title":"Prospective survey of acute osteoarticular infections in a French paediatric orthopedic surgery unit","volume":"19","author":"Ferroni","year":"2013","journal-title":"Clin. Microbiol. Infect."},{"issue":"10","key":"10.1016\/j.ejphar.2025.177458_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy246","article-title":"Correction of linezolid-induced myelotoxicity after switch to tedizolid in a patient requiring suppressive antimicrobial therapy for multidrug-resistant Staphylococcus epidermidis prosthetic-joint infection","volume":"5","author":"Ferry","year":"2018","journal-title":"Open Forum Infect. Dis."},{"issue":"7","key":"10.1016\/j.ejphar.2025.177458_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab351","article-title":"Safety of tedizolid as suppressive antimicrobial therapy for patients with complex implant-associated bone and joint infection due to multidrug-resistant gram-positive pathogens: results from the TediSAT cohort study","volume":"8","author":"Ferry","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.ejphar.2025.177458_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.550853","article-title":"Arthroscopic \"debridement and implant retention\" with local administration of exebacase (lysin CF-301) followed by suppressive tedizolid as salvage therapy in elderly patients for relapsing multidrug-resistant S. Epidermidis prosthetic knee infection","volume":"8","author":"Ferry","year":"2021","journal-title":"Front. Med."},{"issue":"7","key":"10.1016\/j.ejphar.2025.177458_bib22","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1128\/AAC.00431-13","article-title":"In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions","volume":"57","author":"Flanagan","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177458_bib23","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1128\/AAC.03684-14","article-title":"Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function","volume":"59","author":"Flanagan","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"14","key":"10.1016\/j.ejphar.2025.177458_bib24","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.3390\/molecules26144280","article-title":"Oxazolidinone antibiotics: chemical, biological and analytical aspects","volume":"26","author":"Foti","year":"2021","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.ejphar.2025.177458_bib25","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1302\/0301-620X.33B1.110","article-title":"First recurrence of osteomyelitis eighty years after infection","volume":"33-B","author":"Gallie","year":"1951","journal-title":"J Bone Joint Surg Br"},{"issue":"1","key":"10.1016\/j.ejphar.2025.177458_bib26","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1186\/s12879-018-3550-6","article-title":"Factors predictive of relapse in adult bacterial osteomyelitis of long bones","volume":"18","author":"Garcia Del Pozo","year":"2018","journal-title":"BMC Infect. Dis."},{"issue":"10459","key":"10.1016\/j.ejphar.2025.177458_bib27","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","article-title":"Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050","volume":"404","year":"2024","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ejphar.2025.177458_bib28","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02432-17","article-title":"Pharmacokinetics of tedizolid in an obese patient after bariatric surgery","volume":"62","author":"Gr\u00e9goire","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.ejphar.2025.177458_bib90","doi-asserted-by":"crossref","DOI":"10.1002\/cl2.1230","article-title":"PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis","volume":"18","author":"Haddaway","year":"2022","journal-title":"Campbell Systematic Reviews"},{"key":"10.1016\/j.ejphar.2025.177458_bib29","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2147\/IDR.S56691","article-title":"Profile of tedizolid phosphate and its potential in the treatment of acute bacterial skin and skin structure infections","volume":"8","author":"Hall","year":"2015","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.ejphar.2025.177458_bib30","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.2147\/DDDT.S164515","article-title":"Linezolid: a review of its properties, function, and use in critical care","volume":"12","author":"Hashemian","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"issue":"2","key":"10.1016\/j.ejphar.2025.177458_bib31","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.artd.2020.03.008","article-title":"Corynebacterium total hip and knee arthroplasty prosthetic joint infections","volume":"6","author":"Hernandez","year":"2022","journal-title":"Arthroplast Today"},{"issue":"2","key":"10.1016\/j.ejphar.2025.177458_bib32","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/cid\/ciad576","article-title":"Antibacterial resistance leadership group. Moving beyond mortality: development and application of a desirability of outcome ranking (DOOR) endpoint for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia","volume":"78","author":"Howard-Anderson","year":"2024","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"10.1016\/j.ejphar.2025.177458_bib33","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1517\/13543784.2012.660250","article-title":"Tedizolid (TR-701): a new oxazolidinone with enhanced potency","volume":"21","author":"Kanafani","year":"2012","journal-title":"Expet Opin. Invest. Drugs"},{"issue":"7","key":"10.1016\/j.ejphar.2025.177458_bib34","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1093\/jac\/dkx097","article-title":"Correction of myelotoxicity after switch of linezolid to tedizolid for prolonged treatments","volume":"72","author":"Khatchatourian","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"issue":"8","key":"10.1016\/j.ejphar.2025.177458_bib35","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2146\/ajhp130482","article-title":"Tedizolid: a new oxazolidinone antimicrobial","volume":"71","author":"Kisgen","year":"2014","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"9","key":"10.1016\/j.ejphar.2025.177458_bib36","doi-asserted-by":"crossref","first-page":"627","DOI":"10.5414\/CP204007","article-title":"Efficacy and safety of tedizolid in a patient with linezolid-induced neutropenia: a case report","volume":"59","author":"Kobayashi","year":"2021","journal-title":"Int. J. Clin. Pharm. Ther."},{"issue":"10","key":"10.1016\/j.ejphar.2025.177458_bib37","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2106\/JBJS.N.01350","article-title":"3rd. Trends in the epidemiology of osteomyelitis: a population-based study, 1969 to 2009","volume":"97","author":"Kremers","year":"2015","journal-title":"J Bone Joint Surg Am"},{"issue":"1","key":"10.1016\/j.ejphar.2025.177458_bib38","first-page":"37","article-title":"Bone and joint infections caused by gram-negative bacteria","volume":"50","author":"Kucisec-Tepes","year":"1996","journal-title":"Acta Med. Croat."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177458_bib39","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s40121-019-00279-0","article-title":"Retrospective real-world evaluation of outcomes in patients with skin and soft structure infections treated with tedizolid in an outpatient setting","volume":"9","author":"Kullar","year":"2020","journal-title":"Infect. Dis. Ther."},{"issue":"3","key":"10.1016\/j.ejphar.2025.177458_bib40","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/antibiotics8030137","article-title":"Tedizolid versus linezolid for the treatment of acute bacterial skin and skin structure infection: a systematic review and meta-analysis","volume":"8","author":"Lan","year":"2019","journal-title":"Antibiotics"},{"key":"10.1016\/j.ejphar.2025.177458_bib41","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.medmal.2018.02.004","article-title":"Key features of bone and joint infections following the implementation of reference centers in France","volume":"48","author":"Laurent","year":"2018","journal-title":"Med. Maladies Infect."},{"key":"10.1016\/j.ejphar.2025.177458_bib42","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jpra.2023.12.009","article-title":"First-ever ankle arthrodesis with the Capanna technique in an infected open fracture","volume":"39","author":"Lav\u00eda","year":"2023","journal-title":"JPRAS Open"},{"issue":"1","key":"10.1016\/j.ejphar.2025.177458_bib43","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/230949901602400118","article-title":"Use of erythrocyte sedimentation rate and C-reactive protein to predict osteomyelitis recurrence","volume":"24","author":"Lin","year":"2016","journal-title":"J. Orthop. Surg."},{"issue":"9","key":"10.1016\/j.ejphar.2025.177458_bib44","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/s10096-017-2966-z","article-title":"In vitro activity of tedizolid and linezolid against Staphylococcus epidermidis isolated from prosthetic joint infections","volume":"36","author":"Littorin","year":"2017","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"8S","key":"10.1016\/j.ejphar.2025.177458_bib45","article-title":"Antibiotic therapy for osteoarticular infections in 2023: proposals from the pediatric infectious pathology group (GPIP)","volume":"53","author":"Lorrot","year":"2023","journal-title":"Infect Dis Now"},{"issue":"5","key":"10.1016\/j.ejphar.2025.177458_bib46","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.2106\/JBJS.16.00240","article-title":"Global forum: the burden of bone and joint infections: a growing demand for more resources","volume":"99","author":"Malizos","year":"2017","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.ejphar.2025.177458_bib47","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.mpmed.2021.12.008","article-title":"Bone and joint infections","volume":"50","author":"Mathews","year":"2022","journal-title":"Medicine"},{"issue":"3","key":"10.1016\/j.ejphar.2025.177458_bib48","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/17425255.2017.1290080","article-title":"Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections","volume":"13","author":"McBride","year":"2017","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177458_bib49","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1021\/cb200418f","article-title":"The chemistry of peptidyltransferase center-targeted antibiotics: enzymatic resistance and approaches to countering resistance","volume":"7","author":"McCusker","year":"2012","journal-title":"ACS Chem. Biol."},{"issue":"7","key":"10.1016\/j.ejphar.2025.177458_bib50","article-title":"Safety and tolerability of more than six days of tedizolid treatment","volume":"64","author":"Mensa","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.ejphar.2025.177458_bib51","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1517\/14740330903049706","article-title":"Update on the safety of linezolid","volume":"8","author":"Metaxas","year":"2009","journal-title":"Expet Opin. Drug Saf."},{"issue":"6","key":"10.1016\/j.ejphar.2025.177458_bib52","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jiac.2018.01.010","article-title":"Efficacy, safety and pharmacokinetics of tedizolid versus linezolid in patients with skin and soft tissue infections in Japan - results of a randomised, multicentre phase 3 study","volume":"24","author":"Mikamo","year":"2018","journal-title":"J. Infect. Chemother."},{"issue":"5","key":"10.1016\/j.ejphar.2025.177458_bib53","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01282-23","article-title":"Safety and tolerability of tedizolid as oral treatment for bone and joint infections","volume":"11","author":"Miller","year":"2023","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.ejphar.2025.177458_bib55","series-title":"British national formulary, drugs","year":"2024"},{"key":"10.1016\/j.ejphar.2025.177458_bib56","series-title":"British national formulary, drugs","year":"2024"},{"issue":"12","key":"10.1016\/j.ejphar.2025.177458_bib57","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1469-0691.2009.02761.x","article-title":"Efficacy and tolerance of rifampicin-linezolid compared with rifampicin-cotrimoxazole combinations in prolonged oral therapy for bone and joint infections","volume":"15","author":"Nguyen","year":"2009","journal-title":"Clin. Microbiol. Infect."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177458_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/cis966","article-title":"Infectious Diseases Society of America. Executive summary: diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America","volume":"56","author":"Osmon","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejphar.2025.177458_bib59","doi-asserted-by":"crossref","first-page":"3","DOI":"10.21037\/aoj-20-86","article-title":"Classification and management options for prosthetic joint infection","volume":"7","author":"Pellegrini","year":"2022","journal-title":"Ann Jt"},{"issue":"4","key":"10.1016\/j.ejphar.2025.177458_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2022.115804","article-title":"Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA, Europe, Latin America, and the Asia-Pacific region (2015-2019)","volume":"104","author":"Pfaller","year":"2022","journal-title":"Diagn. Microbiol. Infect. Dis."},{"issue":"8","key":"10.1016\/j.ejphar.2025.177458_bib61","doi-asserted-by":"crossref","first-page":"337","DOI":"10.5194\/jbji-6-337-2021","article-title":"Cost of off-label antibiotic therapy for bone and joint infections: a 6-year prospective monocentric observational cohort study in a referral center for management of complex osteo-articular infections","volume":"6","author":"Pham","year":"2021","journal-title":"J Bone Jt Infect"},{"issue":"4","key":"10.1016\/j.ejphar.2025.177458_bib62","doi-asserted-by":"crossref","first-page":"493","DOI":"10.4155\/fmc.15.6","article-title":"Biofilm formation mechanisms and targets for developing antibiofilm agents","volume":"7","author":"Rabin","year":"2015","journal-title":"Future Med. Chem."},{"issue":"10","key":"10.1016\/j.ejphar.2025.177458_bib63","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1099\/jmm.0.000595","article-title":"In vitro activity of tedizolid and comparator agents against Gram-positive pathogens responsible for bone and joint infections","volume":"66","author":"Ract","year":"2017","journal-title":"J. Med. Microbiol."},{"key":"10.1016\/j.ejphar.2025.177458_bib64","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/rheumatology\/kep220","article-title":"Medical vs surgical treatment for the native joint in septic arthritis: a 6-year, single UK academic centre experience","volume":"48","author":"Ravindran","year":"2009","journal-title":"Rheumatology"},{"issue":"11","key":"10.1016\/j.ejphar.2025.177458_bib65","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.3390\/antibiotics12111560","article-title":"Adverse events associated with prolonged antibiotic therapy for periprosthetic joint infections - a prospective study with a special focus on rifampin","volume":"12","author":"Reinecke","year":"2023","journal-title":"Antibiotics"},{"issue":"5","key":"10.1016\/j.ejphar.2025.177458_bib66","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s40262-017-0601-x","article-title":"Clinical pharmacokinetics and pharmacodynamics of oxazolidinones","volume":"57","author":"Roger","year":"2018","journal-title":"Clin. Pharmacokinet."},{"issue":"13","key":"10.1016\/j.ejphar.2025.177458_bib67","first-page":"1946","article-title":"Antimicrobial resistance: a growing serious threat for global public health","volume":"11","author":"Salam","year":"2023","journal-title":"Health Care"},{"issue":"Suppl. 1","key":"10.1016\/j.ejphar.2025.177458_bib68","doi-asserted-by":"crossref","first-page":"22","DOI":"10.37201\/req\/s01.06.2021","article-title":"Tedizolid: new data and experiences for clinical practice","volume":"34","author":"Salavert","year":"2021","journal-title":"Rev. Espa\u00f1ola Quimioter."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177458_bib69","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.diagmicrobio.2016.01.008","article-title":"In vitro activity of tedizolid against staphylococci isolated from prosthetic joint infections","volume":"85","author":"Schmidt-Malan","year":"2016","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.ejphar.2025.177458_bib70","unstructured":"Scottish Medicines Consortium, NHS Scotland. Tedizolid phosphate 200mg film-coated tablets and 200mg powder for concentrate for solution for infusion (Sivextro\u00ae) [Internet]. Cubist (UK) Limited\/Merck Sharp & Dohme Limited, editor.: https:\/\/www.scottishmedicines.org.uk\/media\/2362\/tedizolid_phosphate_sivextro_final_july_2015_for_website.pdf (accessed July 2024)."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177458_bib71","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/antibiotics10010004","article-title":"Tolerance of prolonged oral tedizolid for prosthetic joint infections: results of a multicentre prospective study","volume":"10","author":"Senneville","year":"2020","journal-title":"Antibiotics"},{"key":"10.1016\/j.ejphar.2025.177458_bib72","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1749-6632.2011.06330.x","article-title":"The oxazolidinones: past, present, and future","volume":"1241","author":"Shaw","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"2","key":"10.1016\/j.ejphar.2025.177458_bib73","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/IPC.0000000000000469","article-title":"Successful treatment of prosthetic joint infection due to vancomycin-resistant enterococci with tedizolid","volume":"25","author":"Si","year":"2017","journal-title":"Infect. Dis. Clin. Pract."},{"issue":"2","key":"10.1016\/j.ejphar.2025.177458_bib74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5704\/MOJ.2107.001","article-title":"Explaining osteomyelitis and prosthetic joint infections (PJI) in terms of biofilm - a review","volume":"15","author":"Singh","year":"2021","journal-title":"Malays Orthop J"},{"key":"10.1016\/j.ejphar.2025.177458_bib75","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40545-016-0087-1","article-title":"Impact of switching from intravenous to oral linezolid therapy in Japanese patients: a retrospective cohort study","volume":"9","author":"Tanaka","year":"2016","journal-title":"J Pharm Policy Pract"},{"key":"10.1016\/j.ejphar.2025.177458_bib76","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijid.2019.02.005","article-title":"Antibiotic penetration into bone and joints: an updated review","volume":"81","author":"Thabit","year":"2019","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.ejphar.2025.177458_bib77","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.744182","article-title":"EUCLIDS consortium. Osteoarticular infections in pediatric hospitals in Europe: a prospective cohort study from the euclids consortium","volume":"10","author":"Trobisch","year":"2022","journal-title":"Front Pediatr"},{"issue":"1","key":"10.1016\/j.ejphar.2025.177458_bib78","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/14787210.2021.1932463","article-title":"Intravenous fosfomycin for the treatment of patients with bone and joint infections: a review","volume":"20","author":"Tsegka","year":"2022","journal-title":"Expert Rev. Anti Infect. Ther."},{"issue":"7","key":"10.1016\/j.ejphar.2025.177458_bib79","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jiac.2022.04.003","article-title":"Correction of thrombocytopenia caused by linezolid with scheduled sequential tedizolid use in patients with vertebral osteomyelitis by antibiotic resistant Gram-positive organisms","volume":"28","author":"Ueda","year":"2022","journal-title":"J. Infect. Chemother."},{"issue":"14","key":"10.1016\/j.ejphar.2025.177458_bib82","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1517\/14656566.8.14.2381","article-title":"Linezolid: effectiveness and safety for approved and off-label indications","volume":"8","author":"Vardakas","year":"2007","journal-title":"Expet Opin. Pharmacother."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177458_bib83","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/138920009787048446","article-title":"Association of pharmacokinetic and pharmacodynamic aspects of linezolid with infection outcome","volume":"10","author":"Vardakas","year":"2009","journal-title":"Curr. Drug Metabol."},{"issue":"11","key":"10.1016\/j.ejphar.2025.177458_bib84","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1093\/jac\/dkad276","article-title":"Prolonged use of linezolid in bone and joint infections: a retrospective analysis of adverse effects","volume":"78","author":"Veerman","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejphar.2025.177458_bib85","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ijid.2021.06.055","article-title":"Comparison of the in vitro activity of linezolid, tedizolid, sutezolid, and delpazolid against rapidly growing mycobacteria isolated in Beijing, China","volume":"109","author":"Wen","year":"2021","journal-title":"Int. J. Infect. Dis."},{"issue":"8","key":"10.1016\/j.ejphar.2025.177458_bib86","first-page":"555","article-title":"Tedizolid phosphate (sivextro): a second-generation oxazolidinone to treat acute bacterial skin and skin structure infections","volume":"39","author":"Wong","year":"2014","journal-title":"P T"},{"issue":"2","key":"10.1016\/j.ejphar.2025.177458_bib87","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10096-020-04015-2","article-title":"Tedizolid: a service evaluation in a large UK teaching hospital","volume":"40","author":"York","year":"2021","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"3","key":"10.1016\/j.ejphar.2025.177458_bib88","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s40265-015-0352-7","article-title":"Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens","volume":"75","author":"Zhanel","year":"2015","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.ejphar.2025.177458_bib89","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12941-024-00733-z","article-title":"Evaluation of targeted sequencing for pathogen identification in bone and joint infections: a cohort study from China","volume":"23","author":"Zhang","year":"2024","journal-title":"Ann. Clin. Microbiol. Antimicrob."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925002122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925002122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:28:50Z","timestamp":1762144130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925002122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":87,"alternative-id":["S0014299925002122"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177458","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tedizolid for osteoarticular infections: Evaluation of the published evidence","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177458","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"177458"}}